Exercise-Induced Vasculitis in a Patient With Negative Ultrasound Venous Reflux Study: A Mimic of Stasis Dermatitis

Article Type
Changed
Tue, 02/16/2021 - 11:05

To the Editor:

The transient and generic appearance of exercise-induced vasculitis (EIV) makes it a commonly misdiagnosed condition. The lesion often is only encountered through photographs brought by the patient or by taking a thorough history. The lack of findings on clinical inspection and the generic appearance of EIV may lead to misdiagnosis as stasis dermatitis due to its presentation as erythematous lesions on the medial lower legs.

A 68-year-old woman with no notable medical history was referred to our clinic for suspected stasis dermatitis. At presentation, no lesions were identified on the legs, but she brought photographs of an erythematous urticarial eruption on the medial lower legs, extending from just above the sock line to the mid-calves (Figure). The eruptions had occurred over the last 16 years, typically presenting suddenly after playing tennis or an extended period of walking and spontaneously resolving in 4 days. The lesions were painless, restricted to the calves, and were not pruritic, though the initial presentation 16 years prior included pruritic pigmented patches on the anterior thighs. Because the condition spontaneously improved within days, no treatment was attempted. An ultrasound venous reflux study ruled out venous reflux and stasis dermatitis.

Exercise-induced vasculitis
Exercise-induced vasculitis. A, Erythematous purpuric lesions on the medial aspect of the left lower leg with a distal linear delineation at the sock line. B, Urticarial erythematous eruption on the medial aspect of the right lower leg.


Our patient stated that her 64-year-old sister had reported the same presentation over the last 8 years. Her physical activity was limited strictly to walking, and the lesions occurred after walking for many hours during the day in the heat, involving the medial aspects of the lower legs extending from the ankles to the full length of the calves. Her eruption was warm but was not painful or pruritic. It resolved spontaneously after 5 days with no therapy.

Our patient was advised to wear compression stockings as a preventative measure, but she did not adhere to these recommendations, stating it was impractical to wear compression garments while playing tennis.

Exercise-induced vasculitis most commonly is seen in the medial aspects of the lower extremities as an erythematous urticarial eruption or pigmented purpuric plaque rapidly occurring after a period of exercise.1,2 Lesions often are symmetric and can be pruritic and painful with a lack of systemic symptoms.3 These generic clinical manifestations may lead to a misdiagnosis of stasis dermatitis. One case report included initial treatment of presumptive cellulitis.4 Important clinical findings include a sparing of skin compressed by tight clothing such as socks, a lack of systemic symptoms, rapid appearance after exercise, and spontaneous resolution within a few days. No correlation with chronic venous disease has been demonstrated, as EIV can occur in patients with or without chronic venous insufficiency.5 Duplex ultrasound evaluation showed no venous reflux in our patient.

The pathophysiology of EIV remains unknown, but the concept of exercise-altered microcirculation has been proposed. Heat generated from exercise is normally dissipated by thermoregulatory mechanisms such as cutaneous vasodilation and sweat.1,6 When exercise is extended, done concomitantly in the heat, or performed in legs with preexisting edema or substantial adipose tissue that limit heat attenuation, the thermoregulatory capacity is overloaded and heat-induced muscle fiber breakdown occurs.1,7 Atrophy impairs the skeletal muscle’s ability to pump the increased venous return demanded by exercise to the heart, leading to backflow of venous return and eventual venous stasis.1 Reduction of venous return together with cutaneous vasodilation is thought to induce erythrocyte extravasation.



Histologic examination demonstrates features of leukocytoclastic vasculitis with perivascular lymphocytic and neutrophilic infiltrates.2 Erythrocyte extravasation, IgM deposits, and identification of C3 also have been reported.8,9 The spontaneous resolution of EIV has led to treatment efforts being focused on preventative measures. Several cases have reported some degree of success in preventing EIV with compression therapy, venoactive drugs, systemic steroids, and application of topical steroids before exercise.3

The clinical morphology and lower leg location of EIV leads to a common misdiagnosis of stasis dermatitis. Clinical history of a transient nature is the mainstay in the diagnosis of EIV, and ultrasound venous reflux study may be required in some cases. Preventative measures are superior to treatment and mainly include compression therapy.

References
  1. Ramelet AA. Exercise-induced vasculitis. J Eur Acad Dermatol Venereol. 2006;20:423-427.
  2. Kelly RI, Opie J, Nixon R. Golfer’s vasculitis. Australas J Dermatol. 2005;46:11-14.
  3. Ramelet AA. Exercise-induced purpura. Dermatology. 2004;208:293-296.
  4. Cushman D, Rydberg L. A general rehabilitation inpatient with exercise-induced vasculitis. PM R. 2013;5:900-902.
  5. Veraart JC, Prins M, Hulsmans RF, et al. Influence of endurance exercise on the venous refilling time of the leg. Phlebology. 1994;23:120-123.
  6. Noakes T. Fluid replacement during marathon running. Clin J Sport Med. 2003;13:309-318.
  7. Armstrong RB. Muscle damage and endurance events. Sports Med. 1986;3:370-381.
  8. Prins M, Veraart JC, Vermeulen AH, et al. Leucocytoclastic vasculitis induced by prolonged exercise. Br J Dermatol. 1996;134:915-918.
  9. Sagdeo A, Gormley RH, Wanat KA, et al. Purpuric eruption on the feet of a healthy young woman. “flip-flop vasculitis” (exercise-induced vasculitis). JAMA Dermatol. 2013;149:751-756.
Article PDF
Author and Disclosure Information

Drs. Sundaresan and Silapunt are from the University of Texas McGovern Medical School, Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Issue
Cutis - 107(2)
Publications
Topics
Page Number
E10-E11
Sections
Author and Disclosure Information

Drs. Sundaresan and Silapunt are from the University of Texas McGovern Medical School, Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Author and Disclosure Information

Drs. Sundaresan and Silapunt are from the University of Texas McGovern Medical School, Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Article PDF
Article PDF

To the Editor:

The transient and generic appearance of exercise-induced vasculitis (EIV) makes it a commonly misdiagnosed condition. The lesion often is only encountered through photographs brought by the patient or by taking a thorough history. The lack of findings on clinical inspection and the generic appearance of EIV may lead to misdiagnosis as stasis dermatitis due to its presentation as erythematous lesions on the medial lower legs.

A 68-year-old woman with no notable medical history was referred to our clinic for suspected stasis dermatitis. At presentation, no lesions were identified on the legs, but she brought photographs of an erythematous urticarial eruption on the medial lower legs, extending from just above the sock line to the mid-calves (Figure). The eruptions had occurred over the last 16 years, typically presenting suddenly after playing tennis or an extended period of walking and spontaneously resolving in 4 days. The lesions were painless, restricted to the calves, and were not pruritic, though the initial presentation 16 years prior included pruritic pigmented patches on the anterior thighs. Because the condition spontaneously improved within days, no treatment was attempted. An ultrasound venous reflux study ruled out venous reflux and stasis dermatitis.

Exercise-induced vasculitis
Exercise-induced vasculitis. A, Erythematous purpuric lesions on the medial aspect of the left lower leg with a distal linear delineation at the sock line. B, Urticarial erythematous eruption on the medial aspect of the right lower leg.


Our patient stated that her 64-year-old sister had reported the same presentation over the last 8 years. Her physical activity was limited strictly to walking, and the lesions occurred after walking for many hours during the day in the heat, involving the medial aspects of the lower legs extending from the ankles to the full length of the calves. Her eruption was warm but was not painful or pruritic. It resolved spontaneously after 5 days with no therapy.

Our patient was advised to wear compression stockings as a preventative measure, but she did not adhere to these recommendations, stating it was impractical to wear compression garments while playing tennis.

Exercise-induced vasculitis most commonly is seen in the medial aspects of the lower extremities as an erythematous urticarial eruption or pigmented purpuric plaque rapidly occurring after a period of exercise.1,2 Lesions often are symmetric and can be pruritic and painful with a lack of systemic symptoms.3 These generic clinical manifestations may lead to a misdiagnosis of stasis dermatitis. One case report included initial treatment of presumptive cellulitis.4 Important clinical findings include a sparing of skin compressed by tight clothing such as socks, a lack of systemic symptoms, rapid appearance after exercise, and spontaneous resolution within a few days. No correlation with chronic venous disease has been demonstrated, as EIV can occur in patients with or without chronic venous insufficiency.5 Duplex ultrasound evaluation showed no venous reflux in our patient.

The pathophysiology of EIV remains unknown, but the concept of exercise-altered microcirculation has been proposed. Heat generated from exercise is normally dissipated by thermoregulatory mechanisms such as cutaneous vasodilation and sweat.1,6 When exercise is extended, done concomitantly in the heat, or performed in legs with preexisting edema or substantial adipose tissue that limit heat attenuation, the thermoregulatory capacity is overloaded and heat-induced muscle fiber breakdown occurs.1,7 Atrophy impairs the skeletal muscle’s ability to pump the increased venous return demanded by exercise to the heart, leading to backflow of venous return and eventual venous stasis.1 Reduction of venous return together with cutaneous vasodilation is thought to induce erythrocyte extravasation.



Histologic examination demonstrates features of leukocytoclastic vasculitis with perivascular lymphocytic and neutrophilic infiltrates.2 Erythrocyte extravasation, IgM deposits, and identification of C3 also have been reported.8,9 The spontaneous resolution of EIV has led to treatment efforts being focused on preventative measures. Several cases have reported some degree of success in preventing EIV with compression therapy, venoactive drugs, systemic steroids, and application of topical steroids before exercise.3

The clinical morphology and lower leg location of EIV leads to a common misdiagnosis of stasis dermatitis. Clinical history of a transient nature is the mainstay in the diagnosis of EIV, and ultrasound venous reflux study may be required in some cases. Preventative measures are superior to treatment and mainly include compression therapy.

To the Editor:

The transient and generic appearance of exercise-induced vasculitis (EIV) makes it a commonly misdiagnosed condition. The lesion often is only encountered through photographs brought by the patient or by taking a thorough history. The lack of findings on clinical inspection and the generic appearance of EIV may lead to misdiagnosis as stasis dermatitis due to its presentation as erythematous lesions on the medial lower legs.

A 68-year-old woman with no notable medical history was referred to our clinic for suspected stasis dermatitis. At presentation, no lesions were identified on the legs, but she brought photographs of an erythematous urticarial eruption on the medial lower legs, extending from just above the sock line to the mid-calves (Figure). The eruptions had occurred over the last 16 years, typically presenting suddenly after playing tennis or an extended period of walking and spontaneously resolving in 4 days. The lesions were painless, restricted to the calves, and were not pruritic, though the initial presentation 16 years prior included pruritic pigmented patches on the anterior thighs. Because the condition spontaneously improved within days, no treatment was attempted. An ultrasound venous reflux study ruled out venous reflux and stasis dermatitis.

Exercise-induced vasculitis
Exercise-induced vasculitis. A, Erythematous purpuric lesions on the medial aspect of the left lower leg with a distal linear delineation at the sock line. B, Urticarial erythematous eruption on the medial aspect of the right lower leg.


Our patient stated that her 64-year-old sister had reported the same presentation over the last 8 years. Her physical activity was limited strictly to walking, and the lesions occurred after walking for many hours during the day in the heat, involving the medial aspects of the lower legs extending from the ankles to the full length of the calves. Her eruption was warm but was not painful or pruritic. It resolved spontaneously after 5 days with no therapy.

Our patient was advised to wear compression stockings as a preventative measure, but she did not adhere to these recommendations, stating it was impractical to wear compression garments while playing tennis.

Exercise-induced vasculitis most commonly is seen in the medial aspects of the lower extremities as an erythematous urticarial eruption or pigmented purpuric plaque rapidly occurring after a period of exercise.1,2 Lesions often are symmetric and can be pruritic and painful with a lack of systemic symptoms.3 These generic clinical manifestations may lead to a misdiagnosis of stasis dermatitis. One case report included initial treatment of presumptive cellulitis.4 Important clinical findings include a sparing of skin compressed by tight clothing such as socks, a lack of systemic symptoms, rapid appearance after exercise, and spontaneous resolution within a few days. No correlation with chronic venous disease has been demonstrated, as EIV can occur in patients with or without chronic venous insufficiency.5 Duplex ultrasound evaluation showed no venous reflux in our patient.

The pathophysiology of EIV remains unknown, but the concept of exercise-altered microcirculation has been proposed. Heat generated from exercise is normally dissipated by thermoregulatory mechanisms such as cutaneous vasodilation and sweat.1,6 When exercise is extended, done concomitantly in the heat, or performed in legs with preexisting edema or substantial adipose tissue that limit heat attenuation, the thermoregulatory capacity is overloaded and heat-induced muscle fiber breakdown occurs.1,7 Atrophy impairs the skeletal muscle’s ability to pump the increased venous return demanded by exercise to the heart, leading to backflow of venous return and eventual venous stasis.1 Reduction of venous return together with cutaneous vasodilation is thought to induce erythrocyte extravasation.



Histologic examination demonstrates features of leukocytoclastic vasculitis with perivascular lymphocytic and neutrophilic infiltrates.2 Erythrocyte extravasation, IgM deposits, and identification of C3 also have been reported.8,9 The spontaneous resolution of EIV has led to treatment efforts being focused on preventative measures. Several cases have reported some degree of success in preventing EIV with compression therapy, venoactive drugs, systemic steroids, and application of topical steroids before exercise.3

The clinical morphology and lower leg location of EIV leads to a common misdiagnosis of stasis dermatitis. Clinical history of a transient nature is the mainstay in the diagnosis of EIV, and ultrasound venous reflux study may be required in some cases. Preventative measures are superior to treatment and mainly include compression therapy.

References
  1. Ramelet AA. Exercise-induced vasculitis. J Eur Acad Dermatol Venereol. 2006;20:423-427.
  2. Kelly RI, Opie J, Nixon R. Golfer’s vasculitis. Australas J Dermatol. 2005;46:11-14.
  3. Ramelet AA. Exercise-induced purpura. Dermatology. 2004;208:293-296.
  4. Cushman D, Rydberg L. A general rehabilitation inpatient with exercise-induced vasculitis. PM R. 2013;5:900-902.
  5. Veraart JC, Prins M, Hulsmans RF, et al. Influence of endurance exercise on the venous refilling time of the leg. Phlebology. 1994;23:120-123.
  6. Noakes T. Fluid replacement during marathon running. Clin J Sport Med. 2003;13:309-318.
  7. Armstrong RB. Muscle damage and endurance events. Sports Med. 1986;3:370-381.
  8. Prins M, Veraart JC, Vermeulen AH, et al. Leucocytoclastic vasculitis induced by prolonged exercise. Br J Dermatol. 1996;134:915-918.
  9. Sagdeo A, Gormley RH, Wanat KA, et al. Purpuric eruption on the feet of a healthy young woman. “flip-flop vasculitis” (exercise-induced vasculitis). JAMA Dermatol. 2013;149:751-756.
References
  1. Ramelet AA. Exercise-induced vasculitis. J Eur Acad Dermatol Venereol. 2006;20:423-427.
  2. Kelly RI, Opie J, Nixon R. Golfer’s vasculitis. Australas J Dermatol. 2005;46:11-14.
  3. Ramelet AA. Exercise-induced purpura. Dermatology. 2004;208:293-296.
  4. Cushman D, Rydberg L. A general rehabilitation inpatient with exercise-induced vasculitis. PM R. 2013;5:900-902.
  5. Veraart JC, Prins M, Hulsmans RF, et al. Influence of endurance exercise on the venous refilling time of the leg. Phlebology. 1994;23:120-123.
  6. Noakes T. Fluid replacement during marathon running. Clin J Sport Med. 2003;13:309-318.
  7. Armstrong RB. Muscle damage and endurance events. Sports Med. 1986;3:370-381.
  8. Prins M, Veraart JC, Vermeulen AH, et al. Leucocytoclastic vasculitis induced by prolonged exercise. Br J Dermatol. 1996;134:915-918.
  9. Sagdeo A, Gormley RH, Wanat KA, et al. Purpuric eruption on the feet of a healthy young woman. “flip-flop vasculitis” (exercise-induced vasculitis). JAMA Dermatol. 2013;149:751-756.
Issue
Cutis - 107(2)
Issue
Cutis - 107(2)
Page Number
E10-E11
Page Number
E10-E11
Publications
Publications
Topics
Article Type
Sections
Inside the Article

Practice Points

  • Clinical history of a transient nature is the mainstay in the diagnosis of exercise-induced vasculitis.
  • Exercise-induced vasculitis largely is documented in photographs or by history and may be misdiagnosed as stasis dermatitis due to its clinical morphology and lower leg location.
  • Dermatologists should be aware of this disorder and consider performing further workup to rule out stasis dermatitis and diagnose this mimic.
  • Preventative measures are superior to treatment and mainly include compression therapy.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Article PDF Media

Severe Pretibial Myxedema Refractory to Systemic Immunosuppressants

Article Type
Changed
Wed, 09/11/2019 - 16:07

To the Editor:

A 55-year-old man with a history of Graves disease treated with radioactive iodine and Graves ophthalmopathy was referred to our dermatology clinic by his endocrinologist with a 2-year history of severe pretibial myxedema (PM) that had failed treatment with systemic immunosuppressants after diagnosis by an outside dermatologist in the United Kingdom approximately 2 years prior. In addition to burning pain and difficulty walking associated with progressive “enlarging” of the lower legs and feet (Figure, A and B), the patient reported that he consistently had to find larger shoes (size 13 at the current presentation). His medications included gabapentin for foot pain and levothyroxine for hypothyroidism.

A and B, Severe pretibial myxedema. At baseline, progressive swelling of the lower legs and feet was noted. C and D, At 3-week and 2-month follow-up, respectively, the extremities were notably smaller.

Physical examination revealed diffuse, waxy, indurated, flesh-colored and erythematous plaques and nodules with a peau d’orange appearance on the dorsal feet, ankles, and lower legs. Laboratory evaluation revealed a thyroid stimulating immunoglobulin level of 617% (reference range, <140%) and mild anemia. His thyroid stimulating hormone and free T4 levels, a comprehensive metabolic panel, and lipid panel were all within reference range.



Treatment with oral, intravenous, and intralesional steroids; cyclosporine; and azathioprine were tried prior to presentation to our clinic with no improvement. The patient was started on pentoxifylline (400 mg 3 times daily), intralesional triamcinolone acetonide (5 mg/mL every 3–4 weeks), clobetasol propionate ointment 0.05% under occlusion twice daily, short-stretch bandages, and compression stockings (20–30 mm Hg). The baseline circumference of the extremities also were measured (right ankle, 12 in; left ankle, 11.5 in; right and left mid-plantar feet, 12 in).

At 3-week follow-up, the lesions had flattened with softening of the skin. The patient reported his legs were smaller and he had bought a new pair of shoes at size 8.5 (Figure, C). He noted less pain and difficulty with walking. The circumference of the extremities was measured again (right ankle, 10.2 in; left ankle, 10 in; right and left mid-plantar feet, 10.5 in). The patient continued treatment and was followed for 3 months. At each visit, clinical improvement was noted as well as report of decreased pain while walking (Figure, D).

Pretibial myxedema is a known manifestation of Graves disease that almost always occurs in the presence of Graves ophthalmopathy. Pretibial myxedema occurs in 0.5% to 4.3% of patients with Graves disease and variably manifests as diffuse nonpitting edema or localized, waxy, indurated plaques or nodules.1,2

The proposed pathogenesis of PM is that autoantibodies directed against the thyroid receptors cross-react with the fibroblasts of the skin,2,3 which stimulates the fibroblasts to produce high amounts of glycosaminoglycans, especially hyaluronic acid, in the dermis and subcutis of the pretibial area. It is not known why there is a predilection for the anterior shins, but mechanical factors and dependent position (ie, leg position is lower than the level of the heart) may be involved.4



The mainstay of treatment for PM is topical and intralesional corticosteroids, which may have a benefit in mild to moderate disease; however, in cases of severe disease that is refractory to intralesional and topical corticosteroids under occlusion, more aggressive treatment is required. Systemic immunosuppressants such as cyclosporine, azathioprine, and corticosteroids have proven useful in some but not all cases.5,6

Our patient did not respond to treatment with systemic and intralesional corticosteroids, cyclosporine, or azathioprine before he presented to our clinic; however, the lesions were dramatically improved after 3 weeks of treatment with pentoxifylline, intralesional and topical corticosteroids under occlusion, short-stretch bandages, and compression stockings.

Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves ophthalmology and PM.7 It has been shown to reduce thickness of skin lesions when used in combination with topical or intralesional steroids.3,8 Corticosteroids are thought to block fibroblast-mediated glycosaminoglycan production.3,9 The deposition of mucin, which is comprised of glycosaminoglycans, expands the dermal tissue and causes fluid to accumulate; it also causes compression of dermal lymphatics, worsening the dermal edema. Because fluid accumulates, the use of short-stretch bandages and compression stockings may provide additional benefit, as was seen in our patient, whose shoe size decreased from a 13 to an 8.5 within 3 weeks of treatment.



In conclusion, the combination of pentoxifylline, intralesional and topical corticosteroids under occlusion, short-stretch bandages, and compression garments can cause substantial improvement in severe PM refractory to systemic immunosuppressants.

References
  1. Susser WS, Heermans AG, Chapman MS, et al. Elephantiasic pretibial myxedema: a novel treatment for an uncommon disorder. J Am Acad Dermatol. 2002;46:723-726.
  2. Kriss J. Pathogenesis and treatment of pretibial myxedema. Endocrinol Metab Clin North Am. 1987;16:409-415.
  3. Pineda AM, Tianco EA, Tan JB, et al. Oral pentoxifylline and topical clobetasol propionate ointment in the treatment of pretibial myxoedema, with concomitant improvement of Graves’ ophthalmopathy. J Eur Acad Dermatol Venereol. 2007; 21:1441-1443.
  4. Fatourechi V. Pretibial myxedema. Am J Clin Dermatol. 2005;6:295-309.
  5. Benoit FL, Greenspan FS. Corticoid therapy for pretibial myxedema: observations on the long-acting thyroid stimulator. Ann Intern Med. 1967;66:711-720.
  6. Hanke CW, Bergfeld WF, Guirguis MN, et al. Pretibial myxedema (elephantiasis form): treatment with cytotoxic therapy. Cleve Clin Q. 1983;50:183-188.
  7. Chang CC, Chang TC, Kao SC, et al. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves’ ophthalmopathy and pretibial myxoedema. Acta Endocrinol (Copenh). 1993;129:322-327.
  8. Engin B, Gümüs¸el M, Ozdemir M, et al. Successful combined pentoxifylline and intralesional triamcinolone acetonide treatment of severe pretibial myxedema. Dermatol Online J. 2007;13:16.
  9. Lang PG, Sisson JC, Lynch PJ. Intralesional triamcinolone therapy for pretibial myxedema. Arch Dermatol. 1975;111:197-202.
Article PDF
Author and Disclosure Information

Drs. Silapunt and Agwu are from the University of Texas Medical School at Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, Department of Dermatology, University of Texas Medical School at Houston, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Issue
Cutis - 104(3)
Publications
Topics
Page Number
E1-E3
Sections
Author and Disclosure Information

Drs. Silapunt and Agwu are from the University of Texas Medical School at Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, Department of Dermatology, University of Texas Medical School at Houston, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Author and Disclosure Information

Drs. Silapunt and Agwu are from the University of Texas Medical School at Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, Department of Dermatology, University of Texas Medical School at Houston, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Article PDF
Article PDF

To the Editor:

A 55-year-old man with a history of Graves disease treated with radioactive iodine and Graves ophthalmopathy was referred to our dermatology clinic by his endocrinologist with a 2-year history of severe pretibial myxedema (PM) that had failed treatment with systemic immunosuppressants after diagnosis by an outside dermatologist in the United Kingdom approximately 2 years prior. In addition to burning pain and difficulty walking associated with progressive “enlarging” of the lower legs and feet (Figure, A and B), the patient reported that he consistently had to find larger shoes (size 13 at the current presentation). His medications included gabapentin for foot pain and levothyroxine for hypothyroidism.

A and B, Severe pretibial myxedema. At baseline, progressive swelling of the lower legs and feet was noted. C and D, At 3-week and 2-month follow-up, respectively, the extremities were notably smaller.

Physical examination revealed diffuse, waxy, indurated, flesh-colored and erythematous plaques and nodules with a peau d’orange appearance on the dorsal feet, ankles, and lower legs. Laboratory evaluation revealed a thyroid stimulating immunoglobulin level of 617% (reference range, <140%) and mild anemia. His thyroid stimulating hormone and free T4 levels, a comprehensive metabolic panel, and lipid panel were all within reference range.



Treatment with oral, intravenous, and intralesional steroids; cyclosporine; and azathioprine were tried prior to presentation to our clinic with no improvement. The patient was started on pentoxifylline (400 mg 3 times daily), intralesional triamcinolone acetonide (5 mg/mL every 3–4 weeks), clobetasol propionate ointment 0.05% under occlusion twice daily, short-stretch bandages, and compression stockings (20–30 mm Hg). The baseline circumference of the extremities also were measured (right ankle, 12 in; left ankle, 11.5 in; right and left mid-plantar feet, 12 in).

At 3-week follow-up, the lesions had flattened with softening of the skin. The patient reported his legs were smaller and he had bought a new pair of shoes at size 8.5 (Figure, C). He noted less pain and difficulty with walking. The circumference of the extremities was measured again (right ankle, 10.2 in; left ankle, 10 in; right and left mid-plantar feet, 10.5 in). The patient continued treatment and was followed for 3 months. At each visit, clinical improvement was noted as well as report of decreased pain while walking (Figure, D).

Pretibial myxedema is a known manifestation of Graves disease that almost always occurs in the presence of Graves ophthalmopathy. Pretibial myxedema occurs in 0.5% to 4.3% of patients with Graves disease and variably manifests as diffuse nonpitting edema or localized, waxy, indurated plaques or nodules.1,2

The proposed pathogenesis of PM is that autoantibodies directed against the thyroid receptors cross-react with the fibroblasts of the skin,2,3 which stimulates the fibroblasts to produce high amounts of glycosaminoglycans, especially hyaluronic acid, in the dermis and subcutis of the pretibial area. It is not known why there is a predilection for the anterior shins, but mechanical factors and dependent position (ie, leg position is lower than the level of the heart) may be involved.4



The mainstay of treatment for PM is topical and intralesional corticosteroids, which may have a benefit in mild to moderate disease; however, in cases of severe disease that is refractory to intralesional and topical corticosteroids under occlusion, more aggressive treatment is required. Systemic immunosuppressants such as cyclosporine, azathioprine, and corticosteroids have proven useful in some but not all cases.5,6

Our patient did not respond to treatment with systemic and intralesional corticosteroids, cyclosporine, or azathioprine before he presented to our clinic; however, the lesions were dramatically improved after 3 weeks of treatment with pentoxifylline, intralesional and topical corticosteroids under occlusion, short-stretch bandages, and compression stockings.

Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves ophthalmology and PM.7 It has been shown to reduce thickness of skin lesions when used in combination with topical or intralesional steroids.3,8 Corticosteroids are thought to block fibroblast-mediated glycosaminoglycan production.3,9 The deposition of mucin, which is comprised of glycosaminoglycans, expands the dermal tissue and causes fluid to accumulate; it also causes compression of dermal lymphatics, worsening the dermal edema. Because fluid accumulates, the use of short-stretch bandages and compression stockings may provide additional benefit, as was seen in our patient, whose shoe size decreased from a 13 to an 8.5 within 3 weeks of treatment.



In conclusion, the combination of pentoxifylline, intralesional and topical corticosteroids under occlusion, short-stretch bandages, and compression garments can cause substantial improvement in severe PM refractory to systemic immunosuppressants.

To the Editor:

A 55-year-old man with a history of Graves disease treated with radioactive iodine and Graves ophthalmopathy was referred to our dermatology clinic by his endocrinologist with a 2-year history of severe pretibial myxedema (PM) that had failed treatment with systemic immunosuppressants after diagnosis by an outside dermatologist in the United Kingdom approximately 2 years prior. In addition to burning pain and difficulty walking associated with progressive “enlarging” of the lower legs and feet (Figure, A and B), the patient reported that he consistently had to find larger shoes (size 13 at the current presentation). His medications included gabapentin for foot pain and levothyroxine for hypothyroidism.

A and B, Severe pretibial myxedema. At baseline, progressive swelling of the lower legs and feet was noted. C and D, At 3-week and 2-month follow-up, respectively, the extremities were notably smaller.

Physical examination revealed diffuse, waxy, indurated, flesh-colored and erythematous plaques and nodules with a peau d’orange appearance on the dorsal feet, ankles, and lower legs. Laboratory evaluation revealed a thyroid stimulating immunoglobulin level of 617% (reference range, <140%) and mild anemia. His thyroid stimulating hormone and free T4 levels, a comprehensive metabolic panel, and lipid panel were all within reference range.



Treatment with oral, intravenous, and intralesional steroids; cyclosporine; and azathioprine were tried prior to presentation to our clinic with no improvement. The patient was started on pentoxifylline (400 mg 3 times daily), intralesional triamcinolone acetonide (5 mg/mL every 3–4 weeks), clobetasol propionate ointment 0.05% under occlusion twice daily, short-stretch bandages, and compression stockings (20–30 mm Hg). The baseline circumference of the extremities also were measured (right ankle, 12 in; left ankle, 11.5 in; right and left mid-plantar feet, 12 in).

At 3-week follow-up, the lesions had flattened with softening of the skin. The patient reported his legs were smaller and he had bought a new pair of shoes at size 8.5 (Figure, C). He noted less pain and difficulty with walking. The circumference of the extremities was measured again (right ankle, 10.2 in; left ankle, 10 in; right and left mid-plantar feet, 10.5 in). The patient continued treatment and was followed for 3 months. At each visit, clinical improvement was noted as well as report of decreased pain while walking (Figure, D).

Pretibial myxedema is a known manifestation of Graves disease that almost always occurs in the presence of Graves ophthalmopathy. Pretibial myxedema occurs in 0.5% to 4.3% of patients with Graves disease and variably manifests as diffuse nonpitting edema or localized, waxy, indurated plaques or nodules.1,2

The proposed pathogenesis of PM is that autoantibodies directed against the thyroid receptors cross-react with the fibroblasts of the skin,2,3 which stimulates the fibroblasts to produce high amounts of glycosaminoglycans, especially hyaluronic acid, in the dermis and subcutis of the pretibial area. It is not known why there is a predilection for the anterior shins, but mechanical factors and dependent position (ie, leg position is lower than the level of the heart) may be involved.4



The mainstay of treatment for PM is topical and intralesional corticosteroids, which may have a benefit in mild to moderate disease; however, in cases of severe disease that is refractory to intralesional and topical corticosteroids under occlusion, more aggressive treatment is required. Systemic immunosuppressants such as cyclosporine, azathioprine, and corticosteroids have proven useful in some but not all cases.5,6

Our patient did not respond to treatment with systemic and intralesional corticosteroids, cyclosporine, or azathioprine before he presented to our clinic; however, the lesions were dramatically improved after 3 weeks of treatment with pentoxifylline, intralesional and topical corticosteroids under occlusion, short-stretch bandages, and compression stockings.

Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves ophthalmology and PM.7 It has been shown to reduce thickness of skin lesions when used in combination with topical or intralesional steroids.3,8 Corticosteroids are thought to block fibroblast-mediated glycosaminoglycan production.3,9 The deposition of mucin, which is comprised of glycosaminoglycans, expands the dermal tissue and causes fluid to accumulate; it also causes compression of dermal lymphatics, worsening the dermal edema. Because fluid accumulates, the use of short-stretch bandages and compression stockings may provide additional benefit, as was seen in our patient, whose shoe size decreased from a 13 to an 8.5 within 3 weeks of treatment.



In conclusion, the combination of pentoxifylline, intralesional and topical corticosteroids under occlusion, short-stretch bandages, and compression garments can cause substantial improvement in severe PM refractory to systemic immunosuppressants.

References
  1. Susser WS, Heermans AG, Chapman MS, et al. Elephantiasic pretibial myxedema: a novel treatment for an uncommon disorder. J Am Acad Dermatol. 2002;46:723-726.
  2. Kriss J. Pathogenesis and treatment of pretibial myxedema. Endocrinol Metab Clin North Am. 1987;16:409-415.
  3. Pineda AM, Tianco EA, Tan JB, et al. Oral pentoxifylline and topical clobetasol propionate ointment in the treatment of pretibial myxoedema, with concomitant improvement of Graves’ ophthalmopathy. J Eur Acad Dermatol Venereol. 2007; 21:1441-1443.
  4. Fatourechi V. Pretibial myxedema. Am J Clin Dermatol. 2005;6:295-309.
  5. Benoit FL, Greenspan FS. Corticoid therapy for pretibial myxedema: observations on the long-acting thyroid stimulator. Ann Intern Med. 1967;66:711-720.
  6. Hanke CW, Bergfeld WF, Guirguis MN, et al. Pretibial myxedema (elephantiasis form): treatment with cytotoxic therapy. Cleve Clin Q. 1983;50:183-188.
  7. Chang CC, Chang TC, Kao SC, et al. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves’ ophthalmopathy and pretibial myxoedema. Acta Endocrinol (Copenh). 1993;129:322-327.
  8. Engin B, Gümüs¸el M, Ozdemir M, et al. Successful combined pentoxifylline and intralesional triamcinolone acetonide treatment of severe pretibial myxedema. Dermatol Online J. 2007;13:16.
  9. Lang PG, Sisson JC, Lynch PJ. Intralesional triamcinolone therapy for pretibial myxedema. Arch Dermatol. 1975;111:197-202.
References
  1. Susser WS, Heermans AG, Chapman MS, et al. Elephantiasic pretibial myxedema: a novel treatment for an uncommon disorder. J Am Acad Dermatol. 2002;46:723-726.
  2. Kriss J. Pathogenesis and treatment of pretibial myxedema. Endocrinol Metab Clin North Am. 1987;16:409-415.
  3. Pineda AM, Tianco EA, Tan JB, et al. Oral pentoxifylline and topical clobetasol propionate ointment in the treatment of pretibial myxoedema, with concomitant improvement of Graves’ ophthalmopathy. J Eur Acad Dermatol Venereol. 2007; 21:1441-1443.
  4. Fatourechi V. Pretibial myxedema. Am J Clin Dermatol. 2005;6:295-309.
  5. Benoit FL, Greenspan FS. Corticoid therapy for pretibial myxedema: observations on the long-acting thyroid stimulator. Ann Intern Med. 1967;66:711-720.
  6. Hanke CW, Bergfeld WF, Guirguis MN, et al. Pretibial myxedema (elephantiasis form): treatment with cytotoxic therapy. Cleve Clin Q. 1983;50:183-188.
  7. Chang CC, Chang TC, Kao SC, et al. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves’ ophthalmopathy and pretibial myxoedema. Acta Endocrinol (Copenh). 1993;129:322-327.
  8. Engin B, Gümüs¸el M, Ozdemir M, et al. Successful combined pentoxifylline and intralesional triamcinolone acetonide treatment of severe pretibial myxedema. Dermatol Online J. 2007;13:16.
  9. Lang PG, Sisson JC, Lynch PJ. Intralesional triamcinolone therapy for pretibial myxedema. Arch Dermatol. 1975;111:197-202.
Issue
Cutis - 104(3)
Issue
Cutis - 104(3)
Page Number
E1-E3
Page Number
E1-E3
Publications
Publications
Topics
Article Type
Sections
Inside the Article

Practice Points

  • Pretibial myxedema (PM) is a known manifestation of Graves disease that almost always occurs in the presence of Graves ophthalmopathy.
  • The proposed pathogenesis of PM is cross-reaction of autoantibodies directed against the thyroid receptors with the fibroblasts of the skin. It is not known why there is a predilection for the anterior shins, but mechanical factors and dependent position may be involved.
  • The mainstay of treatment for PM is topical and intralesional corticosteroids, which may have a benefit in mild to moderate disease; however, in cases of severe disease that is refractory to intralesional and topical corticosteroids under occlusion, more aggressive treatment is required.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media

Linear Terra Firma–Forme Dermatosis of the Midline Back

Article Type
Changed
Thu, 01/10/2019 - 13:49
Display Headline
Linear Terra Firma–Forme Dermatosis of the Midline Back

Terra firma–forme dermatosis (TFFD) was first described by Duncan et al,1 in 1987 and is characterized by brown to black pigmented plaques on the skin that cannot be removed with soap and water but are easily wiped away with isopropyl alcohol. Since that publication, relatively few case reports and case series have been published. We present a case of linear TFFD on the midline back of a 46-year-old woman.

Case Report

A 46-year-old woman presented to our clinic for evaluation of a lesion on the back that had been present for 3 years. An initial diagnosis of acanthosis nigricans or lichen simplex chronicus was made and treatment with topical triamcinolone cream 0.1% was initiated. However, after 8 months of treatment, no improvement was observed and the patient returned to our clinic. Her medical history was notable for obesity, type 2 diabetes mellitus, and hypertension. The patient stated that she maintained good hygiene, including daily to twice-daily showers with soap. Physical examination revealed a linear, hyperkeratotic, dark-brown plaque on the midline back extending from the top of the sacrum to the upper back (Figure 1). No other areas of skin involvement were noted. The hyperpigmented scales were easily removed with an isopropyl alcohol swab, which confirmed a diagnosis of TFFD (Figure 2). The patient was given ammonium lactate lotion 12% to apply to the lesion once daily using an applicator stick if the lesion recurred. She reported some improvement during this treatment. She occasionally had recurrent lesions, which were removed with isopropyl alcohol on subsequent dermatology visits.

Figure 1. Linear terra firma–forme dermatosis presenting as a hyperkeratotic, dark-brown plaque on the midline back extending from the top of the sacrum to the upper back.

Figure 2. Linear terra firma–forme dermatosis. The lesion was removed by cleaning with an isopropyl alcohol swab.

Comment

Terra firma–forme dermatosis is an idiopathic condition that, although benign, can cause notable distress to patients. It presents clinically as asymptomatic, brown or black, hyperpigmented, hyperkeratotic, verrucous, or papillomatous plaques or light scaling in some cases.1-4 It can be readily cleared by rubbing with isopropyl alcohol but is resistant to ordinary soap and water.1

Recent reports have shown that TFFD may be more common than once thought.4-6 Although commonly observed in children, TFFD has been reported over a wide range of ages (4–86 years).2-5 The face, ankles, neck, and trunk are the most commonly affected areas.4,7,8 Areas that are less commonly affected often include surgical incision sites as well as the scalp, axillae, back, umbilical area, pubic area, arms, and legs.2-4,8,9 The lesions may be generalized or localized and are sometimes found to be symmetrical.4,10,11

The exact etiology of TFFD is unknown but is believed to be due to melanin retention and alteration or a delay of keratinization that leads to the buildup and compaction of scales.1,2,12 Poor hygiene generally is considered to exclude the diagnosis of TFFD in favor of dermatitis neglecta.6,12,13 Histopathology typically shows epidermal acanthosis, lamellar hyperkeratosis, and orthokeratotic whorls.3,7 However, biopsies seldom are performed due to the ease of diagnosis by removal by cleaning the lesion with isopropyl alcohol.

The diagnosis is confirmed by resolution of the rash after cleaning with isopropyl alcohol.1 Further confirmation of this diagnosis can be achieved through dermoscopy, as large, polygonal, platelike, brown scales can be found arranged together giving a mosaic pattern.6 In addition to cleaning with isopropyl alcohol,5,8 other treatments have shown efficacy for more resistant cases of TFFD, including topical keratolytic agents (eg, lactic acid, urea lotion).4,14

Conclusion

Terra firma–forme dermatosis is a condition that if recognized early, may provide treatment satisfaction through immediate removal of the lesions. Physicians should keep TFFD in their differential during evaluation of patients with asymptomatic, hyperpigmented, hyperkeratotic plaques. Awareness of TFFD is important, as early diagnosis can prevent unnecessary treatment and diagnostic workup.

References
  1. Duncan CW, Tschen JA, Knox JM. Terra firma-forme dermatosis. Arch Dermatol. 1987;123:567-569.
  2. Browning J, Rosen T. Terra firma­forme dermatosis revisited. Dermatol Online J. 2005;11:11-13.
  3. Ashique KT, Kaliyadan F, Goyal T. Terra firma-forme dermatosis: report of a series of 11 cases and a brief review of the literature. Int J Dermatol. 2016;55:769-774.
  4. Berk DR. Terra firma-forme dermatosis: a retrospective review of 31 patients. Pediatr Dermatol. 2012;29:297-300.
  5. Greywal T, Cohen PR. Terra firma-forme dermatosis: a report of ten individuals with Duncan’s dirty dermatosis and literature review. Dermatol Pract Concept. 2015;5:29-33.
  6. Abdel-Razek MM, Fathy H. Terra firm-forme dermatosis: case series and dermoscopic features. Dermatol Online J. 2015;21:4-7.
  7. Akkash L, Badran D, Al-Omari AQ. Terra firma forme dermatosis. case series and review of the literature. J Dtsch Dermatol Ges. 2009;7:102-107.
  8. O’Brien TJ, Hall AP. Terra firma-forme dermatosis. Aust J Dermatol. 1997;38:163-164.
  9. Guarneri C, Guarneri F, Cannavò SP. Terra firma-forme dermatosis. Int J Dermatol. 2008;47:482-484.
  10. Santarpia M, Guarneri C. Terra firma-forme dermatosis. Eur J Intern Med. 2016;34:1-2.
  11. Panchal K, Bhalla N, Salunke P, et al. Extensive terra firma forme dermatosis (TFFD): a rare presentation. Indian Dermatol Online J. 2015;6:458-459.
  12. Erkek E, Sahin S, Cetin ED, et al. Terra firma­forme dermatosis revisited. Indian J Dermatol Venereol Leprol. 2012;78:358-360.
  13. Poskitt L, Wayte J, Wojnarowska F, et al. ‘Dermatitis neglecta’: unwashed dermatosis. Br J Dermatol. 1995;132:827-829.
  14. Unal E, Guarneri C, Chokoeva AA, et al. Terra firma-forme dermatosis [published online October 21, 2016]. Wien Med Wochenschr. 2017;167:66-69.
Article PDF
Author and Disclosure Information

Mr. Freemyer and Dr. Silapunt are from the McGovern Medical School, University of Texas, Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Issue
Cutis - 101(3)
Publications
Topics
Page Number
205-206
Sections
Author and Disclosure Information

Mr. Freemyer and Dr. Silapunt are from the McGovern Medical School, University of Texas, Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Author and Disclosure Information

Mr. Freemyer and Dr. Silapunt are from the McGovern Medical School, University of Texas, Houston. Dr. Silapunt is from the Department of Dermatology. Dr. Migden is from the Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston.

The authors report no conflict of interest.

Correspondence: Sirunya Silapunt, MD, 6655 Travis St, Ste 980, Houston, TX 77030 ([email protected]).

Article PDF
Article PDF

Terra firma–forme dermatosis (TFFD) was first described by Duncan et al,1 in 1987 and is characterized by brown to black pigmented plaques on the skin that cannot be removed with soap and water but are easily wiped away with isopropyl alcohol. Since that publication, relatively few case reports and case series have been published. We present a case of linear TFFD on the midline back of a 46-year-old woman.

Case Report

A 46-year-old woman presented to our clinic for evaluation of a lesion on the back that had been present for 3 years. An initial diagnosis of acanthosis nigricans or lichen simplex chronicus was made and treatment with topical triamcinolone cream 0.1% was initiated. However, after 8 months of treatment, no improvement was observed and the patient returned to our clinic. Her medical history was notable for obesity, type 2 diabetes mellitus, and hypertension. The patient stated that she maintained good hygiene, including daily to twice-daily showers with soap. Physical examination revealed a linear, hyperkeratotic, dark-brown plaque on the midline back extending from the top of the sacrum to the upper back (Figure 1). No other areas of skin involvement were noted. The hyperpigmented scales were easily removed with an isopropyl alcohol swab, which confirmed a diagnosis of TFFD (Figure 2). The patient was given ammonium lactate lotion 12% to apply to the lesion once daily using an applicator stick if the lesion recurred. She reported some improvement during this treatment. She occasionally had recurrent lesions, which were removed with isopropyl alcohol on subsequent dermatology visits.

Figure 1. Linear terra firma–forme dermatosis presenting as a hyperkeratotic, dark-brown plaque on the midline back extending from the top of the sacrum to the upper back.

Figure 2. Linear terra firma–forme dermatosis. The lesion was removed by cleaning with an isopropyl alcohol swab.

Comment

Terra firma–forme dermatosis is an idiopathic condition that, although benign, can cause notable distress to patients. It presents clinically as asymptomatic, brown or black, hyperpigmented, hyperkeratotic, verrucous, or papillomatous plaques or light scaling in some cases.1-4 It can be readily cleared by rubbing with isopropyl alcohol but is resistant to ordinary soap and water.1

Recent reports have shown that TFFD may be more common than once thought.4-6 Although commonly observed in children, TFFD has been reported over a wide range of ages (4–86 years).2-5 The face, ankles, neck, and trunk are the most commonly affected areas.4,7,8 Areas that are less commonly affected often include surgical incision sites as well as the scalp, axillae, back, umbilical area, pubic area, arms, and legs.2-4,8,9 The lesions may be generalized or localized and are sometimes found to be symmetrical.4,10,11

The exact etiology of TFFD is unknown but is believed to be due to melanin retention and alteration or a delay of keratinization that leads to the buildup and compaction of scales.1,2,12 Poor hygiene generally is considered to exclude the diagnosis of TFFD in favor of dermatitis neglecta.6,12,13 Histopathology typically shows epidermal acanthosis, lamellar hyperkeratosis, and orthokeratotic whorls.3,7 However, biopsies seldom are performed due to the ease of diagnosis by removal by cleaning the lesion with isopropyl alcohol.

The diagnosis is confirmed by resolution of the rash after cleaning with isopropyl alcohol.1 Further confirmation of this diagnosis can be achieved through dermoscopy, as large, polygonal, platelike, brown scales can be found arranged together giving a mosaic pattern.6 In addition to cleaning with isopropyl alcohol,5,8 other treatments have shown efficacy for more resistant cases of TFFD, including topical keratolytic agents (eg, lactic acid, urea lotion).4,14

Conclusion

Terra firma–forme dermatosis is a condition that if recognized early, may provide treatment satisfaction through immediate removal of the lesions. Physicians should keep TFFD in their differential during evaluation of patients with asymptomatic, hyperpigmented, hyperkeratotic plaques. Awareness of TFFD is important, as early diagnosis can prevent unnecessary treatment and diagnostic workup.

Terra firma–forme dermatosis (TFFD) was first described by Duncan et al,1 in 1987 and is characterized by brown to black pigmented plaques on the skin that cannot be removed with soap and water but are easily wiped away with isopropyl alcohol. Since that publication, relatively few case reports and case series have been published. We present a case of linear TFFD on the midline back of a 46-year-old woman.

Case Report

A 46-year-old woman presented to our clinic for evaluation of a lesion on the back that had been present for 3 years. An initial diagnosis of acanthosis nigricans or lichen simplex chronicus was made and treatment with topical triamcinolone cream 0.1% was initiated. However, after 8 months of treatment, no improvement was observed and the patient returned to our clinic. Her medical history was notable for obesity, type 2 diabetes mellitus, and hypertension. The patient stated that she maintained good hygiene, including daily to twice-daily showers with soap. Physical examination revealed a linear, hyperkeratotic, dark-brown plaque on the midline back extending from the top of the sacrum to the upper back (Figure 1). No other areas of skin involvement were noted. The hyperpigmented scales were easily removed with an isopropyl alcohol swab, which confirmed a diagnosis of TFFD (Figure 2). The patient was given ammonium lactate lotion 12% to apply to the lesion once daily using an applicator stick if the lesion recurred. She reported some improvement during this treatment. She occasionally had recurrent lesions, which were removed with isopropyl alcohol on subsequent dermatology visits.

Figure 1. Linear terra firma–forme dermatosis presenting as a hyperkeratotic, dark-brown plaque on the midline back extending from the top of the sacrum to the upper back.

Figure 2. Linear terra firma–forme dermatosis. The lesion was removed by cleaning with an isopropyl alcohol swab.

Comment

Terra firma–forme dermatosis is an idiopathic condition that, although benign, can cause notable distress to patients. It presents clinically as asymptomatic, brown or black, hyperpigmented, hyperkeratotic, verrucous, or papillomatous plaques or light scaling in some cases.1-4 It can be readily cleared by rubbing with isopropyl alcohol but is resistant to ordinary soap and water.1

Recent reports have shown that TFFD may be more common than once thought.4-6 Although commonly observed in children, TFFD has been reported over a wide range of ages (4–86 years).2-5 The face, ankles, neck, and trunk are the most commonly affected areas.4,7,8 Areas that are less commonly affected often include surgical incision sites as well as the scalp, axillae, back, umbilical area, pubic area, arms, and legs.2-4,8,9 The lesions may be generalized or localized and are sometimes found to be symmetrical.4,10,11

The exact etiology of TFFD is unknown but is believed to be due to melanin retention and alteration or a delay of keratinization that leads to the buildup and compaction of scales.1,2,12 Poor hygiene generally is considered to exclude the diagnosis of TFFD in favor of dermatitis neglecta.6,12,13 Histopathology typically shows epidermal acanthosis, lamellar hyperkeratosis, and orthokeratotic whorls.3,7 However, biopsies seldom are performed due to the ease of diagnosis by removal by cleaning the lesion with isopropyl alcohol.

The diagnosis is confirmed by resolution of the rash after cleaning with isopropyl alcohol.1 Further confirmation of this diagnosis can be achieved through dermoscopy, as large, polygonal, platelike, brown scales can be found arranged together giving a mosaic pattern.6 In addition to cleaning with isopropyl alcohol,5,8 other treatments have shown efficacy for more resistant cases of TFFD, including topical keratolytic agents (eg, lactic acid, urea lotion).4,14

Conclusion

Terra firma–forme dermatosis is a condition that if recognized early, may provide treatment satisfaction through immediate removal of the lesions. Physicians should keep TFFD in their differential during evaluation of patients with asymptomatic, hyperpigmented, hyperkeratotic plaques. Awareness of TFFD is important, as early diagnosis can prevent unnecessary treatment and diagnostic workup.

References
  1. Duncan CW, Tschen JA, Knox JM. Terra firma-forme dermatosis. Arch Dermatol. 1987;123:567-569.
  2. Browning J, Rosen T. Terra firma­forme dermatosis revisited. Dermatol Online J. 2005;11:11-13.
  3. Ashique KT, Kaliyadan F, Goyal T. Terra firma-forme dermatosis: report of a series of 11 cases and a brief review of the literature. Int J Dermatol. 2016;55:769-774.
  4. Berk DR. Terra firma-forme dermatosis: a retrospective review of 31 patients. Pediatr Dermatol. 2012;29:297-300.
  5. Greywal T, Cohen PR. Terra firma-forme dermatosis: a report of ten individuals with Duncan’s dirty dermatosis and literature review. Dermatol Pract Concept. 2015;5:29-33.
  6. Abdel-Razek MM, Fathy H. Terra firm-forme dermatosis: case series and dermoscopic features. Dermatol Online J. 2015;21:4-7.
  7. Akkash L, Badran D, Al-Omari AQ. Terra firma forme dermatosis. case series and review of the literature. J Dtsch Dermatol Ges. 2009;7:102-107.
  8. O’Brien TJ, Hall AP. Terra firma-forme dermatosis. Aust J Dermatol. 1997;38:163-164.
  9. Guarneri C, Guarneri F, Cannavò SP. Terra firma-forme dermatosis. Int J Dermatol. 2008;47:482-484.
  10. Santarpia M, Guarneri C. Terra firma-forme dermatosis. Eur J Intern Med. 2016;34:1-2.
  11. Panchal K, Bhalla N, Salunke P, et al. Extensive terra firma forme dermatosis (TFFD): a rare presentation. Indian Dermatol Online J. 2015;6:458-459.
  12. Erkek E, Sahin S, Cetin ED, et al. Terra firma­forme dermatosis revisited. Indian J Dermatol Venereol Leprol. 2012;78:358-360.
  13. Poskitt L, Wayte J, Wojnarowska F, et al. ‘Dermatitis neglecta’: unwashed dermatosis. Br J Dermatol. 1995;132:827-829.
  14. Unal E, Guarneri C, Chokoeva AA, et al. Terra firma-forme dermatosis [published online October 21, 2016]. Wien Med Wochenschr. 2017;167:66-69.
References
  1. Duncan CW, Tschen JA, Knox JM. Terra firma-forme dermatosis. Arch Dermatol. 1987;123:567-569.
  2. Browning J, Rosen T. Terra firma­forme dermatosis revisited. Dermatol Online J. 2005;11:11-13.
  3. Ashique KT, Kaliyadan F, Goyal T. Terra firma-forme dermatosis: report of a series of 11 cases and a brief review of the literature. Int J Dermatol. 2016;55:769-774.
  4. Berk DR. Terra firma-forme dermatosis: a retrospective review of 31 patients. Pediatr Dermatol. 2012;29:297-300.
  5. Greywal T, Cohen PR. Terra firma-forme dermatosis: a report of ten individuals with Duncan’s dirty dermatosis and literature review. Dermatol Pract Concept. 2015;5:29-33.
  6. Abdel-Razek MM, Fathy H. Terra firm-forme dermatosis: case series and dermoscopic features. Dermatol Online J. 2015;21:4-7.
  7. Akkash L, Badran D, Al-Omari AQ. Terra firma forme dermatosis. case series and review of the literature. J Dtsch Dermatol Ges. 2009;7:102-107.
  8. O’Brien TJ, Hall AP. Terra firma-forme dermatosis. Aust J Dermatol. 1997;38:163-164.
  9. Guarneri C, Guarneri F, Cannavò SP. Terra firma-forme dermatosis. Int J Dermatol. 2008;47:482-484.
  10. Santarpia M, Guarneri C. Terra firma-forme dermatosis. Eur J Intern Med. 2016;34:1-2.
  11. Panchal K, Bhalla N, Salunke P, et al. Extensive terra firma forme dermatosis (TFFD): a rare presentation. Indian Dermatol Online J. 2015;6:458-459.
  12. Erkek E, Sahin S, Cetin ED, et al. Terra firma­forme dermatosis revisited. Indian J Dermatol Venereol Leprol. 2012;78:358-360.
  13. Poskitt L, Wayte J, Wojnarowska F, et al. ‘Dermatitis neglecta’: unwashed dermatosis. Br J Dermatol. 1995;132:827-829.
  14. Unal E, Guarneri C, Chokoeva AA, et al. Terra firma-forme dermatosis [published online October 21, 2016]. Wien Med Wochenschr. 2017;167:66-69.
Issue
Cutis - 101(3)
Issue
Cutis - 101(3)
Page Number
205-206
Page Number
205-206
Publications
Publications
Topics
Article Type
Display Headline
Linear Terra Firma–Forme Dermatosis of the Midline Back
Display Headline
Linear Terra Firma–Forme Dermatosis of the Midline Back
Sections
Inside the Article

Practice Points

  • Terra firma-forme dermatosis (TFFD) is an idiopathic condition characterized by asymptomatic hyperpigmented and hyperkeratotic plaques that are resistant to removal with soap and water.
  • Diagnosis and cure of TFFD can be achieved through removal by rubbing with isopropyl alcohol.
  • Increased awareness of the clinical presentation and treatment of TFFD may help patients avoid unnecessary treatment and workup and leads to immediate resolution of the condition.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article PDF Media